Cytomegalovirus Infection in Seronegative Patients Treated With Prophylaxis: Case-Controlled Study
Abstract Primary cytomegalovirus (CMV) infection is common in infancy with approximately 90% to 95% of subjects developing antibodies against this virus. CMV seronegative renal allograft recipients generally receive this infection with a graft or with blood transfusions, showing a high morbidity and...
Gespeichert in:
| Veröffentlicht in: | Transplantation proceedings 2007-09, Vol.39 (7), p.2231-2232 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2232 |
|---|---|
| container_issue | 7 |
| container_start_page | 2231 |
| container_title | Transplantation proceedings |
| container_volume | 39 |
| creator | Moreno de la Higuera Díaz, M.A Calvo Romero, N Sánchez-Fructuoso, A Conesa, J Marques Vidas, M Prats, D Barrientos Guzmán, A |
| description | Abstract Primary cytomegalovirus (CMV) infection is common in infancy with approximately 90% to 95% of subjects developing antibodies against this virus. CMV seronegative renal allograft recipients generally receive this infection with a graft or with blood transfusions, showing a high morbidity and mortality. Prophylaxis in these patients has shown good results; however, the published studies have included a small number of patients. Our case-controlled study evaluated 163 kidney transplant recipients: 76 seronegatives for CMV and 87 seropositive for CMV as controls. The evaluated parameters were: CMV infection, CMV disease, renal function, and survival of the patient and graft. We studied our experience among CMV seronegative patients treated with various prophylaxis guidelines. Our conclusions were that CMV prophylaxis in seronegative patients was effective because it showed a risk of infection that was equal (or even less) than that in seropositive patients and revealed a delay in the onset of the disease. CMV seronegativity may be a positive prognostic factor for graft survival. |
| doi_str_mv | 10.1016/j.transproceed.2007.07.074 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68308560</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0041134507009086</els_id><sourcerecordid>68308560</sourcerecordid><originalsourceid>FETCH-LOGICAL-c463t-d4cd3eec642d1bbe158e8a2af50f1b2cfc36f7afba938602e479edf5a2fc63cf3</originalsourceid><addsrcrecordid>eNqNkttq3DAQQEVpaDZpf6GYQvvmrW6W7TwUinsLBBLYlD4KWR412nqlrSQv9d9Hm13akqeAYBBzZkYcDUJvCF4STMT79TIF5eI2eA0wLCnG9fLh8GdoQZqalVRQ9hwtMOakJIxXp-gsxjXOd8rZC3RK6qZpCa8XqO_m5DfwU41-Z8MUi0tnQCfrXWFdsYLgXU4mu4PiJgdwKRa3AVSCofhh011xE_z2bh7VHxsvik5FKDvvUvDjmIlVmob5JToxaozw6hjP0fcvn2-7b-XV9dfL7uNVqblgqRy4HhiAFpwOpO-BVA00iipTYUN6qo1mwtTK9KpljcAUeN3CYCpFjRZMG3aO3h36ZjG_J4hJbmzUMI7KgZ-iFA3DTSVwBi8OoA4-xgBGboPdqDBLguXesFzL_w3LvWH5cHgufn2cMvWbnPtbelSagbdHQEWtRpMbaRv_cS1p65q3mft04CA72VkIMursV8NgQ_4BOXj7tPd8eNRGj9bZPPkXzBDXfgouW5dERiqxXO13Yr8SuMa4xY1g9yoWuPY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68308560</pqid></control><display><type>article</type><title>Cytomegalovirus Infection in Seronegative Patients Treated With Prophylaxis: Case-Controlled Study</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Moreno de la Higuera Díaz, M.A ; Calvo Romero, N ; Sánchez-Fructuoso, A ; Conesa, J ; Marques Vidas, M ; Prats, D ; Barrientos Guzmán, A</creator><creatorcontrib>Moreno de la Higuera Díaz, M.A ; Calvo Romero, N ; Sánchez-Fructuoso, A ; Conesa, J ; Marques Vidas, M ; Prats, D ; Barrientos Guzmán, A</creatorcontrib><description>Abstract Primary cytomegalovirus (CMV) infection is common in infancy with approximately 90% to 95% of subjects developing antibodies against this virus. CMV seronegative renal allograft recipients generally receive this infection with a graft or with blood transfusions, showing a high morbidity and mortality. Prophylaxis in these patients has shown good results; however, the published studies have included a small number of patients. Our case-controlled study evaluated 163 kidney transplant recipients: 76 seronegatives for CMV and 87 seropositive for CMV as controls. The evaluated parameters were: CMV infection, CMV disease, renal function, and survival of the patient and graft. We studied our experience among CMV seronegative patients treated with various prophylaxis guidelines. Our conclusions were that CMV prophylaxis in seronegative patients was effective because it showed a risk of infection that was equal (or even less) than that in seropositive patients and revealed a delay in the onset of the disease. CMV seronegativity may be a positive prognostic factor for graft survival.</description><identifier>ISSN: 0041-1345</identifier><identifier>EISSN: 1873-2623</identifier><identifier>DOI: 10.1016/j.transproceed.2007.07.074</identifier><identifier>PMID: 17889147</identifier><identifier>CODEN: TRPPA8</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Antiviral Agents - therapeutic use ; Biological and medical sciences ; Cytomegalovirus Infections - epidemiology ; Cytomegalovirus Infections - prevention & control ; Follow-Up Studies ; Fundamental and applied biological sciences. Psychology ; Fundamental immunology ; Humans ; Immunosuppressive Agents - therapeutic use ; Incidence ; Kidney Transplantation - adverse effects ; Kidney Transplantation - immunology ; Medical sciences ; Postoperative Complications - virology ; Prevention and actions ; Public health. Hygiene ; Public health. Hygiene-occupational medicine ; Reoperation - statistics & numerical data ; Retrospective Studies ; Surgery ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Tissue Donors - statistics & numerical data ; Tissue, organ and graft immunology ; Transfusion Reaction</subject><ispartof>Transplantation proceedings, 2007-09, Vol.39 (7), p.2231-2232</ispartof><rights>Elsevier Inc.</rights><rights>2007 Elsevier Inc.</rights><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c463t-d4cd3eec642d1bbe158e8a2af50f1b2cfc36f7afba938602e479edf5a2fc63cf3</citedby><cites>FETCH-LOGICAL-c463t-d4cd3eec642d1bbe158e8a2af50f1b2cfc36f7afba938602e479edf5a2fc63cf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.transproceed.2007.07.074$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,777,781,786,787,3537,23911,23912,25121,27905,27906,45976</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19197749$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17889147$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Moreno de la Higuera Díaz, M.A</creatorcontrib><creatorcontrib>Calvo Romero, N</creatorcontrib><creatorcontrib>Sánchez-Fructuoso, A</creatorcontrib><creatorcontrib>Conesa, J</creatorcontrib><creatorcontrib>Marques Vidas, M</creatorcontrib><creatorcontrib>Prats, D</creatorcontrib><creatorcontrib>Barrientos Guzmán, A</creatorcontrib><title>Cytomegalovirus Infection in Seronegative Patients Treated With Prophylaxis: Case-Controlled Study</title><title>Transplantation proceedings</title><addtitle>Transplant Proc</addtitle><description>Abstract Primary cytomegalovirus (CMV) infection is common in infancy with approximately 90% to 95% of subjects developing antibodies against this virus. CMV seronegative renal allograft recipients generally receive this infection with a graft or with blood transfusions, showing a high morbidity and mortality. Prophylaxis in these patients has shown good results; however, the published studies have included a small number of patients. Our case-controlled study evaluated 163 kidney transplant recipients: 76 seronegatives for CMV and 87 seropositive for CMV as controls. The evaluated parameters were: CMV infection, CMV disease, renal function, and survival of the patient and graft. We studied our experience among CMV seronegative patients treated with various prophylaxis guidelines. Our conclusions were that CMV prophylaxis in seronegative patients was effective because it showed a risk of infection that was equal (or even less) than that in seropositive patients and revealed a delay in the onset of the disease. CMV seronegativity may be a positive prognostic factor for graft survival.</description><subject>Antiviral Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cytomegalovirus Infections - epidemiology</subject><subject>Cytomegalovirus Infections - prevention & control</subject><subject>Follow-Up Studies</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Fundamental immunology</subject><subject>Humans</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Incidence</subject><subject>Kidney Transplantation - adverse effects</subject><subject>Kidney Transplantation - immunology</subject><subject>Medical sciences</subject><subject>Postoperative Complications - virology</subject><subject>Prevention and actions</subject><subject>Public health. Hygiene</subject><subject>Public health. Hygiene-occupational medicine</subject><subject>Reoperation - statistics & numerical data</subject><subject>Retrospective Studies</subject><subject>Surgery</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Tissue Donors - statistics & numerical data</subject><subject>Tissue, organ and graft immunology</subject><subject>Transfusion Reaction</subject><issn>0041-1345</issn><issn>1873-2623</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkttq3DAQQEVpaDZpf6GYQvvmrW6W7TwUinsLBBLYlD4KWR412nqlrSQv9d9Hm13akqeAYBBzZkYcDUJvCF4STMT79TIF5eI2eA0wLCnG9fLh8GdoQZqalVRQ9hwtMOakJIxXp-gsxjXOd8rZC3RK6qZpCa8XqO_m5DfwU41-Z8MUi0tnQCfrXWFdsYLgXU4mu4PiJgdwKRa3AVSCofhh011xE_z2bh7VHxsvik5FKDvvUvDjmIlVmob5JToxaozw6hjP0fcvn2-7b-XV9dfL7uNVqblgqRy4HhiAFpwOpO-BVA00iipTYUN6qo1mwtTK9KpljcAUeN3CYCpFjRZMG3aO3h36ZjG_J4hJbmzUMI7KgZ-iFA3DTSVwBi8OoA4-xgBGboPdqDBLguXesFzL_w3LvWH5cHgufn2cMvWbnPtbelSagbdHQEWtRpMbaRv_cS1p65q3mft04CA72VkIMursV8NgQ_4BOXj7tPd8eNRGj9bZPPkXzBDXfgouW5dERiqxXO13Yr8SuMa4xY1g9yoWuPY</recordid><startdate>20070901</startdate><enddate>20070901</enddate><creator>Moreno de la Higuera Díaz, M.A</creator><creator>Calvo Romero, N</creator><creator>Sánchez-Fructuoso, A</creator><creator>Conesa, J</creator><creator>Marques Vidas, M</creator><creator>Prats, D</creator><creator>Barrientos Guzmán, A</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20070901</creationdate><title>Cytomegalovirus Infection in Seronegative Patients Treated With Prophylaxis: Case-Controlled Study</title><author>Moreno de la Higuera Díaz, M.A ; Calvo Romero, N ; Sánchez-Fructuoso, A ; Conesa, J ; Marques Vidas, M ; Prats, D ; Barrientos Guzmán, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c463t-d4cd3eec642d1bbe158e8a2af50f1b2cfc36f7afba938602e479edf5a2fc63cf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Antiviral Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cytomegalovirus Infections - epidemiology</topic><topic>Cytomegalovirus Infections - prevention & control</topic><topic>Follow-Up Studies</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Fundamental immunology</topic><topic>Humans</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Incidence</topic><topic>Kidney Transplantation - adverse effects</topic><topic>Kidney Transplantation - immunology</topic><topic>Medical sciences</topic><topic>Postoperative Complications - virology</topic><topic>Prevention and actions</topic><topic>Public health. Hygiene</topic><topic>Public health. Hygiene-occupational medicine</topic><topic>Reoperation - statistics & numerical data</topic><topic>Retrospective Studies</topic><topic>Surgery</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Tissue Donors - statistics & numerical data</topic><topic>Tissue, organ and graft immunology</topic><topic>Transfusion Reaction</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moreno de la Higuera Díaz, M.A</creatorcontrib><creatorcontrib>Calvo Romero, N</creatorcontrib><creatorcontrib>Sánchez-Fructuoso, A</creatorcontrib><creatorcontrib>Conesa, J</creatorcontrib><creatorcontrib>Marques Vidas, M</creatorcontrib><creatorcontrib>Prats, D</creatorcontrib><creatorcontrib>Barrientos Guzmán, A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Transplantation proceedings</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moreno de la Higuera Díaz, M.A</au><au>Calvo Romero, N</au><au>Sánchez-Fructuoso, A</au><au>Conesa, J</au><au>Marques Vidas, M</au><au>Prats, D</au><au>Barrientos Guzmán, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cytomegalovirus Infection in Seronegative Patients Treated With Prophylaxis: Case-Controlled Study</atitle><jtitle>Transplantation proceedings</jtitle><addtitle>Transplant Proc</addtitle><date>2007-09-01</date><risdate>2007</risdate><volume>39</volume><issue>7</issue><spage>2231</spage><epage>2232</epage><pages>2231-2232</pages><issn>0041-1345</issn><eissn>1873-2623</eissn><coden>TRPPA8</coden><abstract>Abstract Primary cytomegalovirus (CMV) infection is common in infancy with approximately 90% to 95% of subjects developing antibodies against this virus. CMV seronegative renal allograft recipients generally receive this infection with a graft or with blood transfusions, showing a high morbidity and mortality. Prophylaxis in these patients has shown good results; however, the published studies have included a small number of patients. Our case-controlled study evaluated 163 kidney transplant recipients: 76 seronegatives for CMV and 87 seropositive for CMV as controls. The evaluated parameters were: CMV infection, CMV disease, renal function, and survival of the patient and graft. We studied our experience among CMV seronegative patients treated with various prophylaxis guidelines. Our conclusions were that CMV prophylaxis in seronegative patients was effective because it showed a risk of infection that was equal (or even less) than that in seropositive patients and revealed a delay in the onset of the disease. CMV seronegativity may be a positive prognostic factor for graft survival.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>17889147</pmid><doi>10.1016/j.transproceed.2007.07.074</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0041-1345 |
| ispartof | Transplantation proceedings, 2007-09, Vol.39 (7), p.2231-2232 |
| issn | 0041-1345 1873-2623 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68308560 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Antiviral Agents - therapeutic use Biological and medical sciences Cytomegalovirus Infections - epidemiology Cytomegalovirus Infections - prevention & control Follow-Up Studies Fundamental and applied biological sciences. Psychology Fundamental immunology Humans Immunosuppressive Agents - therapeutic use Incidence Kidney Transplantation - adverse effects Kidney Transplantation - immunology Medical sciences Postoperative Complications - virology Prevention and actions Public health. Hygiene Public health. Hygiene-occupational medicine Reoperation - statistics & numerical data Retrospective Studies Surgery Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Tissue Donors - statistics & numerical data Tissue, organ and graft immunology Transfusion Reaction |
| title | Cytomegalovirus Infection in Seronegative Patients Treated With Prophylaxis: Case-Controlled Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T22%3A48%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cytomegalovirus%20Infection%20in%20Seronegative%20Patients%20Treated%20With%20Prophylaxis:%20Case-Controlled%20Study&rft.jtitle=Transplantation%20proceedings&rft.au=Moreno%20de%20la%20Higuera%20D%C3%ADaz,%20M.A&rft.date=2007-09-01&rft.volume=39&rft.issue=7&rft.spage=2231&rft.epage=2232&rft.pages=2231-2232&rft.issn=0041-1345&rft.eissn=1873-2623&rft.coden=TRPPA8&rft_id=info:doi/10.1016/j.transproceed.2007.07.074&rft_dat=%3Cproquest_cross%3E68308560%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68308560&rft_id=info:pmid/17889147&rft_els_id=S0041134507009086&rfr_iscdi=true |